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Abstract
AvastinH (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to
serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so
far, it was the aim of the current study to use a gel-based proteomics method for determination of AvastinH-
protein(s). AvastinH was run on two-dimensional gel electrophoresis (2-DE), spots were picked, followed by multi-enzyme
in-gel digestion. Subsequently, the resulting peptides and posttranslational modifications were identified by mass
spectrometry (nano-LC-ESI-MS/MS; HCT and LTQ Orbitrap MS). Heavy and light chains were observed and the 9 spots that
were picked from 2DE-gels were identified as bevacizumab with high sequence coverage. MS/MS results showed multiple
tyrosine nitrations on the AvastinH light and heavy chains that were either represented as nitrotyrosine or as aminotyrosine,
which was shown to be generated from nitrotyrosine under reducing conditions. Protein nitration is known to significantly
change protein functions and interactions and it may well be that some of the adverse effects of the protein drug AvastinH
may be due to this PTM, which may have been generated during production- thus, nitration of AvastinH is a challenge for
the pharmaceutical industry.
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Introduction
AvastinH (bevacizumab) is an antibody widely used in antitumor
therapy with the underlying principle of neutralizing vascular
endothelial growth factor (VEGF) thus moderating tumor growth.
Although no final assessment of the effectiveness of bevacizumab
in large cohorts of cancer patients has been published, it can be
considered a therapeutic antibody with high potential [1-5].
Fatal adverse effects, however, have been reported in tumor
patients treated with this protein drug and in according to a meta-
analysis, bevacizumab therapy was associated with increased
treatment-related mortality [6].
More specifically, bevacizumab treatment may significantly
increase the risk of serious hemorrhage, hypertension, proteinuria,
cardiac toxicity, vascular thromboembolism, gastrointestinal,
dermatological and endocrine toxicity in cancer patients [7-15].
According to the statement by Stone et al. [10], toxicity
management in treatment with anti-angiogenic agents has not
been an endpoint in most studies carried out up to now and there
is therefore a fundamental need for investigations that will
generate more evidence-based practice guidelines.
Vascular side effects may be readily assigned to biological
activity of VEGF inhibition directly whereas others may be due to
other mechanisms, including probable modifications of this
humanized antibody. No information on AvastinH protein
modifications is available so far and the only systematic mass
spectrometrical approach analysing AvastinH was not designed to
characterise protein modifications but rather to determine stability
[16].
The absence of this information formed the rationale for the
current study with the aims to identify and characterise Avastin
protein and protein modifications in order to form the basis for
studies linking protein modifications to adverse side effects. And
indeed, heavy tyrosine nitration, known to modify protein
properties and functions, was observed in the commercially
available medical product.
Materials and Methods
AvastinH was purchased from Roche, Basel, Switzerland, as
manufactured by Genentech, Inc., San Francisco, USA (Batch
number H0102B01).
Samples of 100 mg protein were applied on immobilized pH 3–
10 nonlinear gradient strips. Focusing started at 200 V and the
voltage was gradually increased to 8,000 V at 4 V/min and kept
constant for a further 3 h (approximately 150,000 Vh totally).
Prior to the second dimensional run, strips were equilibrated twice
for 15 min with gentle shaking in 10 mL of SDS equilibration
buffer (50 mM, pH 8.8, Tris-HCl, 6 M urea, 30% v/v glycerol,
2% w/v SDS, trace of bromophenol blue). DTT (1% w/v) was
added at the first incubation for 15 min and 4% (w/v)
iodoacetamide instead of DTT at the second incubation step for
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10–16% gradient SDS-PAGE. After protein fixation for 12 h in
50% methanol and 10% acetic acid, gels were stained with
colloidal Coomassie blue (Novex, San Diego, CA, USA) for 8 h
and excess of dye was washed out from the gels with distilled
water. Apparent molecular weights were determined by running
precision protein standard markers (Bio-Rad Laboratories,
Hercules, CA, USA), covering the range of 10–250 kDa and
isoelectric points of the immobilized pH gradient strips were from
3-10 [17].
Sodium hydrosulfite treatment
In order to verify nitration [18], 50 mM sodium hydrosulfite
(Na2S2O4) (Sigma, Germany) was added to AvastinH in its original
solvent. The reaction mixture was stirred at 23uC for 30 min to
convert 3-nitrotyrosine to 3-aminotyrosine. Subsequently buffer
was exchanged by 25mM ammonium bicarbonate by Amicon
Ultra 10K (Millipore, Billerca, US) 4 times.
In-gel digestion
Selected gel spots were picked for the investigation (Fig. 1). Gel
pieces were put into a 1.5 mL tube and washed with 10 mM
ammonium bicarbonate and 50% acetonitrile (ACN) in 10 mM
ammonium bicarbonate repeatedly. Addition of ACN resulted in
gel shrinking and the shrunk gel plugs were then dried in a
Speedvac Concentrator (Eppendorf, Germany). Dried gel pieces
were re-swollen and in-gel digested with 40 ng/mL trypsin
(Promega, Madison, WI, USA) in digestion buffer (consisting of
5 mM octyl b-D-glucopyranoside (OGP) and 10 mM ammonium
bicarbonate, pH 7.8) and incubated overnight at 37uC. Digestion
with chymotrypsin (Roche Diagnostics), 25 ng/mL was done in 25
mM NH4HCO3 with 5 mM OGP (pH 7.8) at 30uC for 4 h.
Digestion with 40 ng/mL Pepsin (Roche Diagnostics) was done in
0.1M HCL (pH 1) at 37uC for 4 h.
Peptide extractions were performed with 15 mL of 1% formic
acid (FA) in 5 mM OGP for 30 min, 15 mL 0.1% FA for 30 min
and 15 mL 0.1% FA in 20% ACN for 30 min. The extracted
peptides were pooled for nano-LC-ESI-CID/ETD-MS/MS or
LTQ orbitrap MS/MS analyses.
nano-LC-ESI-CID/ETD-MS/MS
The HPLC used was an Ultimate 3000 system (Dionex,
Sunnyvale, CA, USA) equipped with a PepMap100 C-18 trap
column (300 mm65mm) and PepMap100 C-18 analytic column
(75 mm6150 mm). The gradient was (A 50.1% FA in water, B
50.08% FA in ACN) 4–30% B from 0 to 105 min, 80% B from
105 to 110 min, 4% B from 110 to 125 min. An HCT ultra ETD
II (Bruker Daltonics, Bremen, Germany) was used to record
peptide spectra over the mass range of m/z 350–1500, and MS/
MS spectra in information dependent data acquisition over the
mass range of m/z 100–2800. Repeatedly, MS spectra were
recorded followed by three data-dependent CID MS/MS spectra
and three ETD MS/MS spectra generated from three highest
intensity precursor ions. An active exclusion of 0.4 min after two
spectra was used to detect low abundant peptides. The voltage
between ion spray tip and spray shield was set to 1,500 V. Drying
nitrogen gas was heated to 150uC and the flow rate was 10 L/min.
The collision energy was set automatically according to the mass
and charge state of the peptides chosen for fragmentation.
Multiple charged peptides were chosen for MS/MS experiments
due to their good fragmentation characteristics. MS/MS spectra
were interpreted and peak lists were generated by DataAnalysis
4.0 (Bruker Daltonics).
Raw spectra were processed by Mascot Daemon 2.2.2 (Matrix
Science Ltd, London, UK), the search engine was Mascot 2.2.04.
Peptide tolerance was set to 60.2Da, the MS/MS tolerance was
set to 0.6 Da. Carbamidomethylcysteine was set as static,
oxidation of methionine residues as variable modification. An in-
house generated FASTA data base was used for the search
containing the sequences of the AvastinH (http://www.pmda.go.
jp/english/service/pdf/Abastin-Bevacizumab.pdf), common con-
taminants and proteolytic enzymes. The data base contained 330
sequences and 110,409 residues. Mascot identifications required at
least ion scores greater than 20. PTM searches were also done
using the ModiroH software with following parameters: enzyme
selected as used with two maximum missing cleavage sites, a
peptide mass tolerance of 0.2 Da for peptide tolerance, 0.6 Da for
fragment mass tolerance, modification 1 of carbamidomethyl (C)
and modification 2 of methionine oxidation. Searches for
unknown mass shifts, for amino acid substitutions were carried
out and calculation of significance were selected on advanced
PTM explorer search strategies. A list of 172 common modifica-
tions was selected and added to virtually cleaved and fragmented
peptides searched against experimentally obtained MS/MS
spectra [19]. Manual inspection of spectra was carried out in the
experiments reported.
LTQ Orbitrap MS
The LC-MS/MS analysis was carried out on an LTQ-Orbitrap
Velos ETD mass spectrometer (Thermo Scientific, Waltham, MA,
USA). The data acquisition software was XCalibur 2.1.0. The
nanospray source of Proxeon (Thermo Scientific, Waltham, MA,
USA) was used with the distal coated silica capillaries of New
Objective (Woburn, MA, USA). The electrospray voltage was set
to 1,500 V. The mass spectrometer was operated in positive
ionization mode; the survey scan was performed in the orbitrap,
recording a window between 400 and 1,800 m/z. The resolution
was set to 60,000 for full MS and the automatic gain control was
Figure 1. 2-DE image of AvastinH is shown providing assign-
ments of identified protein spots.
doi:10.1371/journal.pone.0034511.g001
Bevacizumab is Heavily Nitrated
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34511set to 1,000,000 ions with a maximal acquisition time of 500 ms.
The instrument was operated in data-dependent acquisition mode.
The minimum MS signal for triggering MS/MS was set to 500,
and m/z values triggering fragmentation were put on an exclusion
list for 30 s. In all cases one microscan was recorded and a
maximum of 20 MS/MS experiments were triggered for the most
intense ions from an MS scan. The lock mass option was enabled,
and polydimethylcyclosiloxane (protonated (Si(CH3)2O)6; m/z
445.120025 Da) was used for internal recalibration of the mass
spectra. CID was applied as fragmentation method with a target
value of 1,000 in the linear ion trap, the maximal acquisition time
was 100 ms, the collision energy was set to 35%, and the Q value
to 0.25. An activation time of 10 ms was applied. Singly charged
ions and ions with unassigned charge states were not fragmented.
Helium was used as collision gas.
Raw spectra were processed by Mascot Daemon 2.2.2 (Matrix
Science Ltd, London, UK), the search engine was Mascot 2.2.04.
Peptide tolerance was set to 62ppm, the MS/MS tolerance was
set to 0.8 Da. Otherwise data mining was carried out as given
above.
Results and Discussion
As shown in Fig. 1 the commercially available protein drug
AvastinH was presenting with several spots. Heavy and light chain
were clearly separated and heavy chain protein showed tracking
while the light chain showed three major spots. Seven spots were
picked and sequence coverages, enzyme that generated matching
peptides, peptide sequences, ion scores and mass errors that were
less than 0.2 Da are provided in Table S1 and Figure S1. Only
spots 2,3,6 and 7 were presenting with tyrosine nitrations. The
proposed multiple protein modifications (PMs) rather than
sequence conflicts or amino acid exchanges observed in the
individual spots resulting from HCT analysis respecting CID and
ETD fragmentations may have been responsible for horizontal
and vertical electrophoretic shifts as given in Table S2A.
LTQ-orbitrap analyses were used to find additional PMs in
some AvastinH spots, and showed the presence of PMs and the
results are demonstrated in Table S2B. PMs observed by both
methods are presented in Table 1. Results on different
modifications of avastinH expression forms are assigned to spot
numbers.
Table 2 shows tyrosine nitrations shown by ion trap using CID
but not by ETD fragmentation as well as using LTQ orbitrap.
On the light chain as well as on the heavy chain of the antibody
(AvastinH) LTQ identified this PM. HCT analysis demonstrated
two tyrosine nitrations on the light chain and three at the heavy
chain. LTQ orbitrap detected five tyrosine nitrations on the light
chain and four on the heavy chain. Nitration was observed as
nitration or as aminotyrosine [20]. Both MS/MS methods
detected nitration of Y192 expressed by nitrotyrosine and
aminotyrosine identification.
To support the identification of nitrotyrosine, AvastinH was
reduced by sodium hydrosulfite and indeed, aminotyrosine on
Y192 was detected (Figure S2), which does not rule out that the
other modifications are not valid: results from different method-
ologies depend on fragmentation and formation of corresponding
ions generated. Misidentifications of tyrosine nitration by a series
of factors was ruled out [21].
Multiple nitrations of the humanised antibody AvastinH may
have chemical and biological consequences: potential changes of
Avastin immunochemistry may include antigenic changes and
nitration has been repeatedly shown to modify this immunological
property and was even leading to autoimmune phenomena [22].
The underlying cause of nitrations cannot be addressed but
chemical modification by manufacturing is as plausible as nitration
that occurred in vivo during primary generation of the antibody as
a posttranslational modification [23]. Details from manufacturing
and production are not available from the supplier or the
corresponding patent (6,054,297 US patent, 2000).
Antibodies against nitrotyrosine have been observed [24] and it
is known that nitrated peptides and proteins are eliciting antibody
formation [25-27]. Moreover, antibodies against nitrated alpha
synuclein produced an inflammatory response in mice that led to
degeneration of dopaminergic neurons [28]. One may also suggest
that nitration not only leads to autoantibody formation but also to
conformational changes of the nitrated protein [29] that in turn
may change antigenic properties and also protein-protein
interactions with unknown functional consequences. Apart from
nitration-induced antigenic changes of epitopes, nitration is known
to impair function of proteins including Mn superoxide dismutase
[30,31].
A major finding indicating pathogenetic or toxic properties of
nitrated proteins was presented recently: assembly of alpha-
synuclein and fibrinogen were deteriorated by nitration of only a
small fraction of proteins [25,32]. As for fibrinogen, nitration is
accelerating the rate of fibrin clot formation [33]. It cannot be
ruled out, therefore, that nitration of AvastinH may lead to side
effects based upon probable disturbed protein-protein interactions
as aggregations that in turn may lead to a series of complications as
listed in the drug information sheet.
As to the underlying cause of tyrosine nitration it remains open,
whether it can be considered as a post-translational modification of
the immunoglobulin AvastinH or technical in nature, or both [34-
38].
Taken together, it remains unclear if the observed nitrations
and other PMs detected on AvastinH may be responsible for
different biological or pharmacotoxicological properties and
Table 1. The modifications verified by HCT and Orbitrap.
Spot Modifications from MODIROH
2 Deamidation: R87, N321, N390
Dihydroxy: Y284
Methylation: T266
Oxidation: M34, M83
4 Deamidation: N321
Dihydroxy: Y284
Hydroxylation: D73
Methylation: E6
Oxidation: M34, M83
6 Amino: Y192
Deamidation: R142, Q199
Methylation: S121, D122, E123
Nitro: Y192
Oxidation: M4
7 Deamidation: Q199
Dihydroxy: Y36, T197
Hydroxylation: K39
Methylation: E123, E195
Oxidation: M4
doi:10.1371/journal.pone.0034511.t001
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batches of the product has to be taken into considerations on
probable toxicity as well, but corresponding in vivo analyses based
upon these findings should be carried out by the manufacturers to
probably save this protein drug that may have strong potential in
tumor therapy.
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